Hereditary risk for the development of breast or ovarian cancer, due to BRCA1 or 2 mutations, along with the respective prophylactic measures, require further investigation, in order to improve the understanding of best clinical practices. This evidence concerns the gene BRCA1 and ovarian carcinoma.